Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib in NF1-related Plexiform Neurofibromas
NCT04954001Phase 2Active, not recruiting
- Sponsor
- Fosun Pharma
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of luvometinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Fosun Pharma. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose and 2 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
luvometinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT04954001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954001.